Royal Bank Of Canada Reiterates “$12.00” Price Target for Neos Therapeutics, Inc. (NEOS)
Neos Therapeutics, Inc. (NASDAQ:NEOS) has been given a $12.00 target price by equities research analysts at Royal Bank Of Canada in a research report issued to clients and investors on Tuesday, MarketBeat.com reports. The brokerage currently has an “outperform” rating on the stock. Royal Bank Of Canada’s price target would suggest a potential upside of 70.21% from the company’s current price.
Several other brokerages also recently weighed in on NEOS. ValuEngine upgraded Neos Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, May 18th. Zacks Investment Research downgraded Neos Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th. Finally, Cantor Fitzgerald initiated coverage on Neos Therapeutics in a report on Monday, July 31st. They issued an “overweight” rating and a $20.00 price target for the company. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. Neos Therapeutics presently has an average rating of “Hold” and a consensus price target of $14.00.
Shares of Neos Therapeutics (NASDAQ:NEOS) opened at 7.05 on Tuesday. The firm’s market cap is $192.89 million. Neos Therapeutics has a 1-year low of $4.85 and a 1-year high of $9.60. The firm’s 50-day moving average price is $6.97 and its 200 day moving average price is $6.96.
Neos Therapeutics (NASDAQ:NEOS) last issued its quarterly earnings results on Tuesday, August 8th. The company reported ($0.83) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.83). The company had revenue of $4.91 million during the quarter. Neos Therapeutics had a negative return on equity of 889.59% and a negative net margin of 511.74%. On average, equities research analysts forecast that Neos Therapeutics will post ($3.20) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Royal Bank Of Canada Reiterates “$12.00” Price Target for Neos Therapeutics, Inc. (NEOS)” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/08/09/royal-bank-of-canada-analysts-give-neos-therapeutics-inc-nasdaqneos-a-12-00-price-target.html.
Hedge funds have recently added to or reduced their stakes in the company. Essex Investment Management Co. LLC purchased a new stake in Neos Therapeutics during the second quarter worth approximately $1,400,000. Russell Investments Group Ltd. increased its stake in Neos Therapeutics by 167.9% in the second quarter. Russell Investments Group Ltd. now owns 270,020 shares of the company’s stock worth $1,971,000 after buying an additional 169,237 shares during the last quarter. Columbus Circle Investors increased its stake in Neos Therapeutics by 156.2% in the second quarter. Columbus Circle Investors now owns 272,934 shares of the company’s stock worth $1,992,000 after buying an additional 166,414 shares during the last quarter. Hunter Associates Investment Management LLC purchased a new stake in Neos Therapeutics during the first quarter worth approximately $360,000. Finally, Falcon Point Capital LLC increased its stake in Neos Therapeutics by 37.7% in the second quarter. Falcon Point Capital LLC now owns 121,563 shares of the company’s stock worth $887,000 after buying an additional 33,284 shares during the last quarter. Institutional investors and hedge funds own 34.45% of the company’s stock.
About Neos Therapeutics
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.